Associations of SLC6A3 gene VNTR polymorphism with the effects of extended-release naltrexone in alcohol dependence: Role of the opioid modulation of dopaminergic tonus

Miroshkin S. S.
Head, Narcology Department¹

Skryabin V. Yu.
Associate Professor, Chair for Narcology²

Timerbulatov I. F.
Doctor of Medicine, Professor, Chair for Narcology²

Sobolev E. S.
Associate Professor, Chair for Narcology²

Sychev D. A.
Academician of the Russian Academy of Sciences, Doctor of Medicine, Professor, Rector²

1Moscow Research and Practical Centre for Addictions, Moscow, Russian Federation
2Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation

Miroshkin Sergei Sergeevich; e-mail: sergofren@mail.ru.

The study had no sponsorship.

None declared.

Background. The dopamine transporter gene SLC6A3 (DAT1) regulates synaptic dopamine levels by directly interacting with the opioid system in the mesolimbic reward pathway. Its VNTR polymorphism may modulate the response to the μ-opioid receptor antagonist naltrexone. Purpose of the study. To evaluate the effect of VNTR SLC6A3 on the efficacy of extended-release naltrexone (ER-N) in alcohol dependence (AD), with a focus on opioid-dopamine interaction as a key mechanism of action of the drug. Material and methods. In a 180-day prospective study, 100 Russian-speaking patients of Slavic origin with AD received monthly injections of PN. Genotyping of VNTR SLC6A3 was performed by PCR with electrophoretic detection of fragments. Validation of 20% of samples by sequencing (ABI 3500xl) confirmed 100% accuracy. The distribution of genotypes corresponded to Hardy-Weinberg equilibrium (χ²=1.32, p=0.25): 10R/10R (n=63), 9R/10R (n=33), 9R/9R (n=4). The duration of remission, adherence to therapy, frequency of relapses, dynamics of pathological craving (PACS scale), as well as phenotypic characteristics (craving structure and type of motivation) were assessed. Results. Carriers of the 9R/10R genotype had the most favourable clinical outcomes: 153.7±33.1 days (p=0.047), completion of therapy – 81.8% (p=0.048), decrease in craving according to PACS =-7.3±2.1 (p<0.001). The 9R/9R group (n=4) was not included in statistical comparisons due to its small size. The risk of relapse in carriers of ≥1 9R allele: OR=0.49 (95% CI: 0.24–0.99; p=0.048). Conclusion: VNTR SLC6A3 may modulate the efficacy of PN by influencing dopaminergic tone, which determines the sensitivity of the opioid system to blockade. Intermediate DAT expression in 9R/10R heterozygotes likely optimises naltrexone's ability to suppress opioid-induced dopamine release in the nucleus accumbens. The data obtained highlight the need to study the polygenic background (including OPRM1) for personalising therapy.

SLC6A3, DAT1, alcohol dependence, extended-release naltrexone, pharmacogenetics, dopamine, relapse

10.29234/2308-9113-2025-13-3-18-30

1. Park S.H., Kim D.J. Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies. Clin Mol Hepatol. 2020; 26(4): 652-661, doi: 10.3350/cmh.2020.0160

2. Alongkronrusmee D., Chiang T., van Rijn R.M. Delta Opioid Pharmacology in Relation to Alcohol Behaviors. Handb Exp Pharmacol. 2018; 247: 199-225, doi: 10.1007/164­_2016­_30

3. Hansson A.C., Gründer G., Hirth N., Noori H.R., Spanagel R., Sommer W.H. Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neurosci Biobehav Rev. 2019; 106: 141-164, doi: 10.1016/j.neubiorev.2018.09.010

4. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., Lee K.S., Linnoila M., Weinberger D.R. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology. 2000; 22(2): 133-139, doi: 10.1016/S0893-133X(99)00099-8

5. Brody A.L., Mandelkern M.A., Olmstead R.E., Scheibal D., Hahn E., Shiraga S., Zamora-Paja E., Farahi J., Saxena S., London E.D., McCracken J.T. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry. 2006; 63(7): 808-816, doi: 10.1001/archpsyc.63.7.808

6. Congdon E., Lesch K.P., Canli T. Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(1): 27-32, doi: 10.1002/ajmg.b.30557

7. Brewer A.J. 3rd, Nielsen D.A., Spellicy C.J., Hamon S.C., Gingrich J., Thompson-Lake D.G., Nielsen E.M., Mahoney J.J. 3rd, Kosten T.R., Newton T.F., De La Garza R. 2nd. Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders. Pharmacogenet Genomics. 2015; 25(6): 296-304, doi: 10.1097/FPC.0000000000000137

8. Flannery B.A., Volpicelli J.R., Pettinati H.M. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999; 23(8): 1289-1295.

9. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987; 334: 1-100, doi: 10.1111/j.1600- 0447.1987.tb10566.x

10. Al’tshuler V.B. Patologicheskoe vlechenie k alkogolju: voprosy kliniki i terapii. [Craving to alcohol: clinical and therapeutic issues.] Moscow: Image, 1994. 216 p. (In Russ.)

11. Dudko T.N. Urovni reabilitacionnogo potenciala narkologicheskih bol'nyh kak osnova differencirovannoj sistemy ih mediko-socia’'noj reabilitacii. [Levels of rehabilitation potential in drug addicts as the basis for a differentiated system of medical and social rehabilitation.] Voprosy narkologii [Issues in Addiction Medicine] 2000; (3):13-21.

12. Fields H.L., Margolis E.B. Understanding opioid reward. Trends Neurosci. 2015; 38(4): 217-225, doi: 10.1016/j.tins.2015.01.002

13. van Dyck C.H., Malison R.T., Jacobsen L.K., Seibyl J.P., Staley J.K., Laruelle M., Baldwin R.M., Innis R.B., Gelernter J. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med. 2005; 46(5): 745-751.

14. van Rijn R.M., Brissett D.I., Whistler J.L. Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety. J Pharmacol Exp Ther. 2010; 335(1): 133-139, doi: 10.1124/jpet.110.170969

15. Koob G.F., Volkow N.D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016; 3(8): 760-77, doi: 10.1016/S2215-0366(16)00104-8

16. Volkow N.D., Baler R.D. NOW vs LATER brain circuits: implications for obesity and addiction. Trends Neurosci. 2015; 38(6): 345-352, doi: 10.1016/j.tins.2015.04.002

17. Goldstein R.Z., Volkow N.D. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011; 12(11): 652-669, doi: 10.1038/nrn3119